Glucocorticoid monotherapy vs. immunosuppressant-combined therapy in retroperitoneal fibrosis: clinical evidence and mechanistic insights from bioinformatics
Clinical evidence from literature and mechanistic insights from bioinformatics both suggest a potential benefit of combination therapy in RPF. However, the evidence remains associative and exploratory. Further randomized controlled trials are warranted to evaluate the potential benefits and risks associated with the addition of immunosuppressants in patients with RPF.
Authors
- Cuiping Pan (ORCID: https://orcid.org/0000-0002-8152-2489)
- Tong Zheng (ORCID: https://orcid.org/0009-0005-1488-2846)
- Yishan Ding
- Hui Gao (ORCID: https://orcid.org/0000-0002-4235-614X)
- Yuexian Shi
- Zhuoyi Wu
Institutions
- Hong Kong University of Science and Technology (HK)
- Peking University (CN)
- Bioscience (China) (CN)
- Beijing Tsinghua Chang Gung Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1186/s40001-026-03856-5
- Primary Topic
- IgG4-Related and Inflammatory Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00